Effects of non-steroidal growth implant and dietary zilpaterol hydrochloride on growth and carcass characteristics of feedlot lambs

The effects of steroidal growth implants alone or in combination with β-adrenergic agonist feed additives have not been studied thoroughly in mutton sheep in South African feedlot conditions. This study investigated the effects of a non-steroidal growth implant zeranol (Ralgro®), alone or in combination with zilpaterol hydrochloride (Zilmax®), on growth performance, carcass characteristics, and selected meat quality traits in 160 SA Mutton Merino ram lambs fed in a commercial feedlot. The experimental design consisted of two Ralgro treatment groups x two Zilmax treatments x two Zilmax feeding periods x 20 animals per treatment group. Lambs were randomly allocated to eight treatment groups, of which one half were implanted with Ralgro after arrival, followed by feed supplementation with Zilmax at two Zilmax feeding periods during the finisher phase, compared with negative control treatments (e.g. no Ralgro or Zilmax; Ralgro + no Zilmax; or no Ralgro + Zilmax). All lambs were fed the grower ration traditionally used by the commercial feedlot, which contained 16.89% crude protein (CP) and 2.94 Mcal/kg dry matter (DM). Zilmax was supplemented in the feed at 40 mg per animal per day and fed for 18 days or 25 days, plus three days withdrawal. Lambs that did not receive the Zilmax treatment were fed the basal diet without Zilmax feed supplementation. Ralgro significantly increased average daily gains (ADG) and cold carcass mass (CCM) of lambs. Lambs supplemented with Zilmax during the finisher phase had higher ADG, greater CCM and increased dressing percentage by ca.1.1% compared with those in the control group. Lambs fed Zilmax for 25 days had higher CCM than those fed for 18 days. The duration of the Zilmax treatment also decreased hide weight, fat thickness and shear force values (tenderness). Zilmax increased ADG and CCM in lambs, particularly if combined with Ralgro implants during the growing phase. The results from this study indicate that the combination of Ralgro implants with Zilmax feed supplementation during the finisher phase had additive effects and increased ADG and CCM of feedlot lambs.Keywords: Growth performance, meat quality, South African Mutton Merino, sheep, Ralgro®, Zilmax

Comparison between the effects of zilpaterol hydrochloride and R-salbutamol fed during the finishing period on the growth and carcass characteristics of feedlot cattle

This study aimed to compare the effects of feeding 60 mg of the β-adrenergic agonist, zilpaterol HCl (Zilmax®), per steer per day versus feeding 120 mg of the β-adrenergic agonist, R-salbutamol (Salbutamate®10%), per steer per day for the last 30 days of the finishing period on the growth, efficiency, and carcass characteristics of 228 typical South African feedlot steers in a completely randomised control study. The steers were slaughtered at the same abattoir after a 3-day withdrawal period. The growth and feedlot parameters included starting mass, slaughter mass, average daily gain, live mass gain, and lean carcass gain. The carcass characteristics included warm (WCW) and cold carcass mass (CCW), carcass length (CL), subcutaneous fat thickness measured over the 13th rib (SCF), dressing percentage, carcass compactness, carcass classification score, age code, and fat code using the South African carcass classification system. The inclusion of zilpaterol HCl as a feed additive resulted in higher growth and efficiency, with an ADG of 1.3 kg/day (P <0.05) in steers fed zilpaterol HCl compared to 1.1 kg/day for steers fed R-salbutamol. Steers in the zilpaterol HCl experimental group had a 12.5 kg higher average slaughter mass, yielding ~3 kg higher calculated lean gain than steers fed R-salbutamol. Steers fed zilpaterol HCl yielded better carcass characteristics of 11.4 kg higher CCW and marginally longer carcasses compared to steers fed Rsalbutamol. Therefore, the overall growth, feedlot performance, and carcass characteristics were higher in the zilpaterol HCl-fed steers than in R-salbutamol-fed steers.http://www.sasas.co.zaam2024Animal and Wildlife SciencesSDG-02:Zero Hunge

Metodología de investigación en sistemas de cultivo en finca

Publicado originalmente por el IRRI bajo el título: A methodology for on-farm cropping systems researc

Spectroscopic examinations of hydro- and glaciovolcanic basaltic tuffs: Modes of alteration and relevance for Mars

Hydro- and glaciovolcanism are processes that have taken place on both Earth and Mars. The amount of materials produced by these processes that are present in the martian surface layer is unknown, but may be substantial. We have used Mars rover analogue analysis techniques to examine altered tuff samples collected from multiple hydrovolcanic features, tuff rings and tuff cones, in the American west and from glaciovolcanic hyaloclastite ridges in Washington state and in Iceland. Analysis methods include VNIR-SWIR reflectance, MWIR thermal emissivity, thin section petrography, XRD, XRF, and Mössbauer spectroscopy. We distinguish three main types of tuff that differ prominently in petrography and VNIR-SWIR reflectance: minimally altered sideromelane tuff, gray to brown colored smectite-bearing tuff, and highly palagonitized tuff. Differences are also observed between the tuffs associated with hydrovolcanic tuff rings and tuff cones and those forming glaciovolcanic hyaloclastite ridges. For the locations sampled, hydrovolcanic palagonite tuffs are more smectite and zeolite rich while the palagonitized hyaloclastites from the sampled sites are largely devoid of zeolites and relatively lacking in smectites as well. The gray to brown colored tuffs are only observed in the hydrovolcanic deposits and appear to represent a distinct alteration pathway, with formation of smectites without associated palagonite formation. This is attributed to lower temperatures and possibly longer time scale alteration. Altered hydro- or glaciovolcanic materials might be recognized on the surface of Mars with rover-based instrumentation based on the results of this study

Star Formation and Dynamics in the Galactic Centre

The centre of our Galaxy is one of the most studied and yet enigmatic places in the Universe. At a distance of about 8 kpc from our Sun, the Galactic centre (GC) is the ideal environment to study the extreme processes that take place in the vicinity of a supermassive black hole (SMBH). Despite the hostile environment, several tens of early-type stars populate the central parsec of our Galaxy. A fraction of them lie in a thin ring with mild eccentricity and inner radius ~0.04 pc, while the S-stars, i.e. the ~30 stars closest to the SMBH (<0.04 pc), have randomly oriented and highly eccentric orbits. The formation of such early-type stars has been a puzzle for a long time: molecular clouds should be tidally disrupted by the SMBH before they can fragment into stars. We review the main scenarios proposed to explain the formation and the dynamical evolution of the early-type stars in the GC. In particular, we discuss the most popular in situ scenarios (accretion disc fragmentation and molecular cloud disruption) and migration scenarios (star cluster inspiral and Hills mechanism). We focus on the most pressing challenges that must be faced to shed light on the process of star formation in the vicinity of a SMBH.Comment: 68 pages, 35 figures; invited review chapter, to be published in expanded form in Haardt, F., Gorini, V., Moschella, U. and Treves, A., 'Astrophysical Black Holes'. Lecture Notes in Physics. Springer 201

Marijuana use associations with pulmonary symptoms and function in Tobacco smokers enrolled in the Subpopulations and Intermediate Outcome Measures in COPD study (SPIROMICS)

Background: Marijuana is often smoked via a filterless cigarette and contains similar chemical makeup as smoked tobacco. There are few publications describing usage patterns and respiratory risks in older adults or in those with chronic obstructive pulmonary disease (COPD). Methods: A cross-sectional analysis of current and former tobacco smokers from the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) study assessed associations between marijuana use and pulmonary outcomes. Marijuana use was defined as never, former (use over 30 days ago), or current (use within 30 days). Respiratory health was assessed using quantitative high-resolution computed tomography (HRCT) scans, pulmonary function tests and questionnaire responses about respiratory symptoms. Results: Of the total 2304 participants, 1130 (49%) never, 982 (43%) former, and 192 (8%) current marijuana users were included. Neither current nor former marijuana use was associated with increased odds of wheeze (odds ratio [OR] 0.87, OR 0.97), cough (OR 1.22; OR 0.93) or chronic bronchitis (OR 0.87; OR 1.00) when compared to never users. Current and former marijuana users had lower quantitative emphysema (P=0.004, P=0.03), higher percent predicted forced expiratory volume in 1 second (FEV1%) (P < 0.001, P < 0.001), and percent predicted forced vital capacity (FVC%) (p < 0.001, P < 0.001). Current marijuana users exhibited higher total tissue volume (P=0.003) while former users had higher air trapping (P < 0.001) when compared to never marijuana users. Conclusions: Marijuana use was found to have little to no association with poor pulmonary health in older current and former tobacco smokers after adjusting for covariates. Higher forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) was observed among current marijuana users. However, higher joint years was associated with more chronic bronchitis symptoms (e.g., wheeze), and this study cannot determine if long-term heavy marijuana smoking in the absence of tobacco smoking is associated with lung symptoms, airflow obstruction, or emphysema, particularly in those who have never smoked tobacco cigarettes

An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

For a decade, The Cancer Genome Atlas (TCGA) program collected clinicopathologic annotation data along with multi-platform molecular profiles of more than 11,000 human tumors across 33 different cancer types. TCGA clinical data contain key features representing the democratized nature of the data collection process. To ensure proper use of this large clinical dataset associated with genomic features, we developed a standardized dataset named the TCGA Pan-Cancer Clinical Data Resource (TCGA-CDR), which includes four major clinical outcome endpoints. In addition to detailing major challenges and statistical limitations encountered during the effort of integrating the acquired clinical data, we present a summary that includes endpoint usage recommendations for each cancer type. These TCGA-CDR findings appear to be consistent with cancer genomics studies independent of the TCGA effort and provide opportunities for investigating cancer biology using clinical correlates at an unprecedented scale. Analysis of clinicopathologic annotations for over 11,000 cancer patients in the TCGA program leads to the generation of TCGA Clinical Data Resource, which provides recommendations of clinical outcome endpoint usage for 33 cancer types

EBMT/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity

Transplantation and immunomodulatio

How well do we understand the reaction rate of C burning?

Carbon burning plays a crucial role in stellar evolution, where this reaction is an important route for the production of heavier elements. A particle-γ coincidence technique that minimizes the backgrounds to which this reaction is subject and provides reliable cross sections has been used at the Argonne National Laboratory to measure fusion cross-sections at deep sub-barrier energies in the 12C+12C system. The corresponding excitation function has been extracted down to a cross section of about 6 nb. This indicates the existence of a broad S-factor maximum for this system. Experimental results are presented and discussed